RecruitingPhase 2NCT05903833
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Studying Vulvar carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AGO Research GmbH
- Principal Investigator
- Linn Wölber, MD PhDUKE Hamburg
- Intervention
- Pembrolizumab(drug)
- Enrollment
- 42 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2025 – 2029
Study locations (15)
- Universitätsklinikum Augsburg, Augsburg, Germany
- Hochtaunus-Kliniken Bad Homburg, Bad Homburg, Germany
- Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
- Universitätsklinikum Düsseldorf, Düsseldorf, Germany
- KEM Kliniken Essen-Mitte, Essen, Germany
- Universitätsklinikum Essen, Essen, Germany
- Universitätsmedizin Göttingen, Göttingen, Germany
- University Hospital Hamburg, Hamburg, Germany
- Klinikum Hanau GmbH, Hanau, Germany
- ZAGO - Zentrum für ambulante gynäkologische Onkologie, Krefeld, Germany
- Universitätsmedizin Mainz, Mainz, Germany
- Universitätsklinikum Mannheim, Manheim, Germany
- Klinikum der Universität München, LMU, München, Germany
- Universitätsklinikum Münster, Münster, Germany
- University Hospital, Tübingen, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05903833 on ClinicalTrials.govOther trials for Vulvar carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06447064Cancer Loyalty Card Study 2 (CLOCS-2)Imperial College London
- RECRUITINGNCT07380698The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological CancerCukurova University
- ENROLLING BY INVITATIONNANCT07023601International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva.Hospital Universitario La Paz
- RECRUITINGNANCT05576831STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide ExcisionBritish Columbia Cancer Agency
- RECRUITINGNANCT06495554Danish Vulva Cancer Recurrence StudyUniversity of Aarhus
- RECRUITINGNANCT06264167NODE (groiN ultrasOunD cancEr)Queensland Centre for Gynaecological Cancer
- ACTIVE NOT RECRUITINGNANCT06694116Charcoal Carbon Black Dye Use in Sentinel Lymph Node Mapping in Early Stage Vulvar CancerIstanbul University
- RECRUITINGPHASE2NCT05905315Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVCThe Netherlands Cancer Institute